ID
22203
Descrizione
A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1 This form is to be completed in/ after Screening Period 2, 1 Month +/- 3 Days, 6 Months +/- 1 week and 12 Months +/- 1 week.
collegamento
https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1
Keywords
versioni (1)
- 22/05/17 22/05/17 -
Caricato su
22 maggio 2017
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
Similar models
FDG Pet Scan Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148
C0808070 (UMLS CUI [1,2])
C0040223 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,2])
C0947611 (UMLS CUI [1,2])
C3174092 (UMLS CUI [1,2])
C0449468 (UMLS CUI [1,2])